RSAR: Post-marketing RX Drug Abuse Surveill Data Denver Health Data Source

Forecast Overview

NAICS

541990

Performance end

3/2026

Program continuity - Option Year 4 services. Allows FDA to conduct active surveillance of ADEs to inform regulatory actions and abuse prevention programs. Contract to obtain post-marketing prescription and over-the-counter drug abuse surveillance data generated from individuals entering or being assessed for substance abuse treatment. Fund Type Rationale: Funding to ensure program continuity. An increase in funding is proposed to increase the granularity of data for the receipt of additional stratified results. The fund type is split between PDUFA and GDUFA and involves all CDER medical products.

Source

Source

HHS SBCX Forecast Export

Source file

Forecast.csv

Official source

Agency forecast source

Last verified

2026-08-31

Agency-published contact: · TBD@fda.hhs.gov

Related Federal Entities

• Department of Health and Human Services · agency
• Regulatory Review Support · related forecast
• Center of Excellence on Compounding for Outsourcing Facilities -Operating Costs · related forecast
• RSAR: Post-marketing RX Drug Abuse Surveillance Data - IBH (Data Source) · related forecast
• Document Room Office Supplies and Equipment · related forecast
• RIM Recompete · related forecast
• Federal Technology Spending Map · spending map
• Federal Opportunity Research · resource